Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

VIR

+ Watchlist+ Portfolio

Vir Biotechnology, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$9.15
52-Week Range
$5.45 – $14.38
Market Cap
$1.65B
P/E (TTM)
—
EPS (TTM)
-1.18
Dividend Yield
0.00%
Advanced Metrics
Price/Book
1.68
PEG Ratio
—
Return on Equity
-21.84%
Return on Assets
-12.47%
Gross Margin
-36.67%
Operating Margin
-70.21%
Profit Margin
-61.03%
Current Ratio
6.30
Debt/Equity
0.10
Total Debt
$90.78M
Free Cash Flow
$-81.92M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$1.20B

Market Snapshot

About

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing immunological treatments for infectious diseases. The company uses antibody platform technologies to develop therapies for diseases including hepatitis B, influenza, HIV, and COVID-19. Vir leverages deep insights into viral immunology to create potentially transformative treatments.